PPT-DURABLE EFFICACY OF DOLUTEGRAVIR (DTG) PLUS LAMIVUDINE (3TC) IN ANTIRETROVIRAL TREATMENT

NAIVE ADULTS WITH HIV1 INFECTION 96WEEK RESULTS FROM THE GEMINI STUDIES 1 Fundación Huesped Buenos Aires Argentina 2 Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán Mexico City Mexico . FLAMINGO. GS-236-0103. ACTG A5257. WAVES. ARIA . Design. Objective. Non inferiority of DTG/ABC/3TC at W48: % HIV RNA < 50 c/mL by intention. to treat, snapshot analysis (lower margin of the 2-sided 95% CI for the difference = - 12%). Generic. HIV . Drugs. on 90-90-90. Esteban Burrone. Medicines Patent Pool. . . Impact in terms of treatment affordability. Impact in making new treatments available faster. Impact in making needed new formulations. Martina Penazzato MD, PhD. Paediatric lead, HIV Department. World Health Organization, Geneva. Background. 1.8 million children were estimated to live with HIV in 2017. In 2017, only 51 % of HIV-exposed infants received EID (by 2mo). Dolutegravir monotherapy vs. dolutegravir/ abacavir / lamivudine for HIV-1-infected virologically suppressed patients: results from the randomized non- inferiority MONCAY trial L. Hocqueloux STARTMRK. GS-US-236-0102 . SINGLE. Walmsley. S. NEJM 2013;369:1807-18. Design. Objective. Non inferiority of DTG at W48: % HIV RNA < 50 c/mL by intention to treat, snapshot analysis (1-sided significance level of 2.5%, lower margin of . Joseph J. Eron, Jr, MD. Professor of Medicine. University of North Carolina. Chapel Hill, North Carolina. Panelists. Constance Benson. Hyman Scott. Annie . Luetkemeyer. Robert . Schooley. Financial Relationships With Commercial Entities. WHO HQ. The role of DTG based regimens in first- and second-line HIV treatment and PEP – Updated WHO recommendations. HIV testing and care continuum (2017). Source: UNAIDS/WHO . estimates. 2016 WHO recommandations for 1st Line ART in . GEMINI 1 and GEMINI 2: Week 48 Data. DTG + 3TC . versus . DTG + TDF-FTC as Initial ART. GEMINI 1 and 2: Background. Source: Cahn P, et al. Lancet. 2019;393:143-55.. Study Design: GEMINI 1 and 2. Background. SPRING-2 Study. Dolutegravir. versus Raltegravir. SPRING-2: Design. Source: . Raffi. F, et al. Lancet. 2013;381:735-43.. Dolutegravir. : 50 mg QD. Fixed-dose NRTI backbone*. (n = 411). Raltegravir. Prepared by:. Brian R. Wood, MD. David H. Spach, MD. Last Updated: January 28, 2021. Dolutegravir (. Tivicay. ) . INSTI. Tivicay. . [TIV-eh-kay]. Dolutegravir. Treatment Naïve. : 50 mg once daily with or without food. 1. ViiV Healthcare, Brentford, UK; . 2. Centre Hospitalier de Tourcoing, Tourcoing, France; . 3. Holdsworth House Medical Brisbane, Queensland, Australia; . 4. CHU Saint-Pierre, Brussels, Belgium; . 5. With Emergence of Comorbidities. Roger J. . Bedimo. , MD. Professor of Medicine. University of Texas Southwestern Medical Center. Dallas, TX. Learning Objectives. On completion of this presentation, learners will be able to:. Andrew Hill, Francois Venter, Eric . Delaporte. , . Simiso. Sokhela, Charles . Kouanfack. , . Michelle Moorhouse. , Kaitlyn McCann, Bryony Simmons. , . Alexandra . Calmy. Disclosures. Speaker fees and honoraria from Gilead Sciences, AbbVie, Cipla, Johnson and Johnson, Sanofi, Pfizer, ViiV Healthcare, Mylan and Southern African HIV Clinicians Society. Associate Dean for Global Health. University of Alabama at Birmingham. Birmingham, Alabama. Cases from the Clinic(. ians. ): . Case. -based Panel Discussion. AU Final: 02/21/17. New York, New York: February 24, 2017.